KFAS
CTKB icon

Keating Financial Advisory Services’s Cytek Biosciences CTKB Stock Holding History

Keating Financial Advisory Services’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-86
Closed -$376 – 2631
2026
Q1 		$376 Buy
86
+84
+4,200% +$397 ﹤0.01% 2307
2025
Q4 		$10 Buy
+2
New +$9 ﹤0.01% 2211

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Keating Financial Advisory Services's CTKB Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 86 shares — an estimated $376 sold.

Keating Financial Advisory Services first reported a position in CTKB in Q4 2025 and held it in 2 quarters. The position peaked at $376 in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Keating Financial Advisory Services reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 86 Cytek Biosciences shares in Q2 2026, an estimated $376.
  • Keating Financial Advisory Services first reported a position in Cytek Biosciences in Q4 2025 and held it in 2 quarters.
  • Keating Financial Advisory Services's Cytek Biosciences position peaked at $376 in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.